유럽에서 오메가-3 지방산으로 정신병에 대한 초고위험 피험자를 대상으로 한 위약 대조 임상시험 (PURPOSE)
The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
PURPOSE is a randomized double-blind placebo-controlled study. Main objective is to assess the effectivity of omega-3 fatty acid treatment in the prevention of psychosis. The primary outcome measure is the rate of transition to psychosis as determined through CAARMS. Subjects in the age range of 13-20 years with a higher chance of developing psychosis, as determined by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo. This study in conducted at 14 sites in 9 countries.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Utrecht, 네덜란드
- Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht
-
-
-
-
-
Bergen, 노르웨이
- Institute of Clinical Medicine, University of Bergen
-
-
-
-
-
Tübingen, 독일
- Department of Child and Adolescent Psychiatry, University of Tübingen
-
-
-
-
-
Zurich, 스위스
- ZKJP University Zürich
-
-
-
-
-
Barcelona, 스페인
- Hospital Clinic de Barcelona
-
Barcelona, 스페인
- Hospital Infantil Passeig Sant Joan de Deu
-
Madrid, 스페인
- Hospital General Universitario Gregorio Marañon
-
Santander, 스페인
- Idival, University of Cantabria, Cibersam Unidad de investigacion en psiquiatria
-
-
-
-
-
Edinburgh, 영국
- Psychiatry, Centre for Clinical Brain Sciences
-
-
-
-
-
Vienna, 오스트리아
- BioPsyC Biopsychosocial Corporation
-
-
-
-
-
Petah Tikva, 이스라엘
- Schneider Children's Medical Center
-
Ramat Gan, 이스라엘
- Tel Hashomer The Sheba Medical Center
-
-
-
-
-
Rome, 이탈리아
- Fondazione Santa Lucia
-
Rome, 이탈리아
- Sapienza University of Rome
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Written informed consent of the subject. For individuals younger than 18 years of age the parents / legal representatives need to give consent, and the subject can provide assent (whether the latter is required depends on local laws and regulations).
- UHR diagnosis as made using the Comprehensive Assessment of At-Risk Mental States (CAARMS) (Yung et al., 2005). Subjects have to meet one or more of the following criteria: (a) attenuated psychotic symptoms, (b) brief limited intermittent psychotic symptoms (a history of one or more episodes of frank psychotic symptoms that resolved spontaneously within 1 week in the past year), or (c) either the presence of schizotypal personality disorder or a family history of psychosis in a first-degree relative, all three together with a recent decline in function.
Exclusion Criteria:
- Any clinically significant medical condition that may influence the results of the trial or affect the ability to take part in a trial.
- Laboratory screening values considered clinically relevant by a medical doctor for transaminases, thyroid hormones or coagulation parameters
- Current or past DSM-IV diagnosis of psychosis, as measured with K-SADS-PL
- Current treatment with an antipsychotic or mood-stabilising agent
- Intake of an antipsychotic or mood-stabilising agent in the two weeks prior to study inclusion
- Intake of an antipsychotic agent equivalent to a total haloperidol use of >50 mg in the six months prior to study inclusion
- A first-degree relative (i.e. parents, offspring or siblings) participating in this study
- UHR diagnosis on the basis of attenuated psychotic symptoms that are entirely explained by acute intoxication
- Current aggression or dangerous behaviour (PANSS G14 score 5 or above)
- Current suicidality / self-harm (PANSS G6 score 7)
- Current DSM-IV diagnosis of alcohol or substance dependence as measured with K-SADS-PL
- Any current or previous neurological disorder, including epilepsy
- History of head injury resulting in unconsciousness lasting at least 1 hour
- IQ < 70
- More than 4 weeks of regular omega-3 supplementation (>2 daily capsules standard strength providing >600 mg combined EPA/DHA) within the last 6 months.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Omega-3 fatty acids
Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months. |
다른 이름들:
|
|
위약 비교기: Placebo
Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Transition Rate
기간: measured starting from baseline up to 2 years post-baseline
|
To compare transition rates to psychosis during 24 months of individual follow-up between the omega-3 fatty acids arm and the placebo arm. Starting point is the first administration of medication at the end of visit 2. Endpoint is the moment that a UHR subject makes a transition to psychosis according to the CAARMS criteria, which can be anytime between baseline and the 2 year post-baseline measurement (or no transition occurs, as only part of the sample is expected to transition). |
measured starting from baseline up to 2 years post-baseline
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Discontinuation Rate
기간: measurement starting at baseline up to 2 years post-baseline
|
how many participants dropped out from the 2-year study, measurement starting at randomisation (baseline) |
measurement starting at baseline up to 2 years post-baseline
|
|
Symptomatology
기간: baseline to 2 years post-baseline
|
change in PANSS total score between baseline and individual follow up after 2 years. The PANSS has a range in total score of min 30 until max 210, with higher values representing more severe symptoms. |
baseline to 2 years post-baseline
|
|
Psychosocial Functioning
기간: measurement started at baseline up to the 2 year timepoint
|
Change in Social and Occupational Functioning Assessment Scale (SOFAS), from baseline to the 2-year timepoint. Min score is 0, max score is 100; higher scores reflects better functioning. |
measurement started at baseline up to the 2 year timepoint
|
|
Intelligence
기간: One time assessment of IQ
|
This is incorrectly added as outcome measure, as IQ does not tend to change over a 2-year period. Here only the assessment at screening is presented. IQ is determined by the WAIS at, with a minimum score of 40, a maximum score of 160. Higher scores represent better cognitive functioning |
One time assessment of IQ
|
|
Blood Levels of Bioactive Lipids
기간: measurement started at baseline up until 6 months
|
Assessment of the 2 components of omega-3 fatty acids (EPA and DHA), change from baseline to 6 months. The 6 month timepoint was selected as the omega-3 fatty acids / placebo treatment ended at that timepoint, even though the primary endpoint (transition to psychosis) ran until 2 years post-baseline. |
measurement started at baseline up until 6 months
|
|
Positive and Negative Symptoms
기간: from baseline to 2 years post-baseline
|
Change in symptomatology will be examined with the Positive and Negative Syndrome Scale (PANSS) as the difference between the assessment at baseline and after 2 years post-baseline, with a score range between min 30 and max 210. Higher scores represent more severe symptoms. |
from baseline to 2 years post-baseline
|
|
Level of Functioning
기간: from baseline to 2 years post-baseline
|
Change in symptomatology will be examined with the Global Assessment of Functioning scale (GAF), from baseline to 2 years post-baseline. Total score ranges from 0 to 100, with higher numbers meaning better functioning. |
from baseline to 2 years post-baseline
|
|
Level of Depression
기간: measured starting at baseline up to 2 years post-baseline
|
Change in symptomatology will be examined with the Beck's Depression Inventory (BDI), starting at baseline up until follow up after 2 years. Total score ranges from 0 to 63, with higher scores reflecting more severe symptoms. |
measured starting at baseline up to 2 years post-baseline
|
|
Role Functioning
기간: measurement started at baseline up until 2 years post-baseline
|
Change in functioning, determined by the Global Functioning Role (GF:R) scale at baseline and follow up up until 2 years. This is a clinician-rated scale from 1 to 10 that measures a person's performance in school or work based on age, independence, and support needs. A score of 10 indicates superior functioning, while a score of 1 indicates extreme dysfunction. |
measurement started at baseline up until 2 years post-baseline
|
|
Social Functioning
기간: measurement started at baseline up until 2 years post-baseline
|
Change in social functioning, determined by the Global Functioning Social (GF:S) scale at baseline and follow up until 2 years. This is a clinician-rated scale from 1 to 10, where higher numbers show better social skills and lower numbers show severe social isolation. |
measurement started at baseline up until 2 years post-baseline
|
공동 작업자 및 조사자
수사관
수사관
- 연구 의자: René Kahn, Prof. Dr., UMC Utrecht
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- ABR54654
- 2015 (미국 NIH 보조금/계약)
- 2015-003503-39 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .